ILSI-Biomed Israel

Long-Awaited Bilski Decision Expected Soon

by GERSON PANITCH, FINNEGAN   June 14, 2010 Patent professionals and U.S. Supreme Court watchers alike on high alert as a Bilski decision is expected before the Court’s 2009 term comes to an end this month.  Perhaps no case is more anticipated than the decision in Bilski v. Doll, especially for those in high-tech fields such as telecom, software, and professional services.  Over a year has passed since the Supreme Court agreed to hear Bilski’s appeal (June 1, 2009), and more than seven ...

ILSI-BioMed 2010 Has Begun!

This morning the ILSI-BioMed Week 2010 has finally been launched, with 7,000 anticipated participants that will take part in lectures and meetings with the experts and seniors of the bio-pharma and medical equipment industry in Israel and abroad. Following the opening words of the event's organizers, ILSI and Kenes, the president of Israel Shimon Peres came up to the stage and surveyed the future of Israel, which will be based on advanced technologies and serve as an example to the entire...

A French Delegation in the Negev

A French delegation has visited today (Sunday, 13.6.2010) at Ben-Gurion University, as the guest of Bio-Negev, the international center for innovation in the biotechnology industry and life sciences in the Negev. The purpose of the visit is to examine potential collaboration between the visitors and the new initiative in the Negev, BGU being one of the partners in the project. Prof. Rivka Carmi, president of the university, places a great amount of value in the initiative, which can be direct...

BioMed 2010 week Innovations: The New Generation of PainShield

NanoVibronix will present the second generation of PainShield – for the treatment of pain and chronic wounds using ultrasound waves Following the commercial success of the first generation PainShield device, for the treatment of (surprise, surprise) pain, especially one that stems from Trigeminal Neualgia, the Israeli company NanoVibronix now reveals the second generation of the device. This time, it has some extra capabilities to treat chronic wounds. NanoVibronix, based in Nesher, is develo...

Israel’s Life Sciences Export On the Rise

The Coming ILSI–Biomed Israel 2010 Week: The Israel Export and International Cooperation Institute: Life Sciences Export Rose by 14% on the First Quarter of 2010, Summing up to the Total of ca. $1.7 Billion “The first 2010 quarter export of the life sciences industry summed up to ca. $1.7 billion, an increase of about 14 percent compared to the same period last year. This increase is derived from a 15.4 percent increase in the export of medications, which has summed up to ca. $1.3 Billion...

Biotech co D Medical files for Nasdaq listing

Biotech co D Medical files for Nasdaq listing: If the offering is successful, it will greatly dilute the holdings of its current shareholders.  The management of medical device holding company D Medical Industries Ltd. (TASE:DMDC) are not deterred by the falls on the Tel Aviv Stock Exchange (TASE) and on Wall Street over the past few weeks. The company today announced that it has filed a draft prospectus with the US Securities and Exchange Commission (SEC) for a public offering and reques...

Human Beta Cells Grown in a Culture

From BioMed Israel Week 2010: A Novel Therapeutic Method Based on the Ability of Stem Cells to Assist in Treating Juvenile Diabetes Will Replace the Insulin Injection Ramot, Tel Aviv University's technology transfer company, will present for the first time a therapeutic approach based on stem cells capability to assist in the treatment of juvenile diabetes, in the Israel BioMed Week 2010, which will be held on the 14th-16th of June in Tel Aviv. The main novelty of the treatment is a br...

Startup Weekly: ProtAb – Antibodies Against Arthritis

ProtAb is a company dedicated to eveloping an antibody for the treatment of Rheumatoid Arthritis and other autoimmune diseases such as Crohn's Disease, and has recently raised $4 million. Name: ProtAb CEO: Shira Yair Sector: Biopharma Medical Field: Autoimmune Diseases Est.: 2005 Stage: Late stage pre-clinical, after series A funding Vision: To develop a novel therapeutics for autoimmune diseases, based on the induction of natural anti-inflammatory mechanisms existing in...

Networking with Five Italian Companies

Five Italian biomedical companies are coming to Israel, and are interested in meeting suitable Israeli business partners It’s not WHAT you know, it’s WHO you know! Relationships are the catalyst for success! Do the above two statements look familiar? They should. They are the axioms of the Networking Theory (name not trademarked, invented on the spot). While networking seems to be the new religion of the business folks, I daresay that it’s been around for quite a bit. Even apes have...

Enzymotec: a $20 M Deal with Daiichi Sankyo

Israeli biotech company Enzymotec Ltd., a developer of active pharmaceutical ingredients for nutritional supplements, has signed a major strategic agreement with Daiichi Sankyo Brazil, a subsidiary of Japanese pharmaceutical company Daiichi Sankyo Co. Ltd. (TSE: 4568). Globes, 6 May Enzymotec and Daiichi Sankyo Brazil will launch Enzymotec's product for the reduction of cholesterol and triglycerides, which Daiichi Sankyo Brazil will market. Daiichi Sankyo Brazil focuses on cardiology a...